Leerink Partnrs Analysts Cut Earnings Estimates for Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Illumina in a report issued on Tuesday, September 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $1.12 for the quarter, down from their previous forecast of $1.13. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s FY2025 earnings at $4.39 EPS.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. Illumina’s revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 earnings per share.

ILMN has been the topic of a number of other reports. UBS Group lifted their price objective on shares of Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Robert W. Baird upped their price target on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $242.00 price objective on shares of Illumina in a research note on Wednesday, August 14th. StockNews.com began coverage on Illumina in a research report on Thursday, August 29th. They issued a “buy” rating for the company. Finally, Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $151.05.

Illumina Stock Up 0.5 %

Shares of Illumina stock opened at $130.21 on Wednesday. Illumina has a 1-year low of $89.00 and a 1-year high of $148.19. The company has a market capitalization of $20.74 billion, a P/E ratio of -15.98 and a beta of 1.15. The business’s fifty day moving average price is $124.26 and its two-hundred day moving average price is $120.54. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of ILMN. Trivant Custom Portfolio Group LLC increased its holdings in shares of Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the period. Versant Capital Management Inc increased its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Industrial Alliance Investment Management Inc. purchased a new stake in Illumina in the 2nd quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after buying an additional 132 shares during the period. Finally, Principal Securities Inc. purchased a new position in shares of Illumina during the 4th quarter valued at $51,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.